EvaluatePharma® - the premier source for pharma and biotech analysis.
Expert integration of financial and product data across historic and forecast timeframes (1986 to 2016) delivers a vast array of analytics by product, company, therapy area, EphMRA ATC code, technology, patent status, deals, license revenues and much more.
|
| Company Profile |
|
|
| Profile
|
26 MAR 2009: Roche acquired Genentech 44.1% stake for $95 per share in cash valued at ~$46.8bn in addition to already owned 55.8% stake valued at approx. $48.7bn (31 DEC 2008).
Genentech (DNA), a San Francisco based Biotech that pioneered recombinant DNA technology.
Within EvaluatePharma, Genentech is classified as an overlapping inactive company and its product sales (1986-2009) overlap with Roche. |
| Listed or Private Company
|
Listed |
| Company Classification
|
Global Majors; Biotechnology |
| Company Website
|
Website
|
|
Full Company Profile Information
| EventAnalyzer - Last Key Event |
|
| Closing Price DateClosing Price Date
|
EventAnalyzer Note
|
Market Cap (US $m)
|
Change (%)
|
Change (+$m)
|
| 3/6/2009 |
6 Mar: Shares rise after Roche raises its bid for the remaining 44% of Genentech it does not already own to $93 per share, valuing the deal at $45.7bn and replacing its previous bid of $42bn or $86.50 per share, and extends its tender offer by a week. |
95,713 |
11.3% |
9,712 |
|
| Top 3 Products (Worldwide Sales 2007/08) |
|
|
| Therapy Area Focus in 2008 |
| Genentech
|
|
2008 |
| WW Rx & OTC Sales By Therapy Area
|
| Main Categories
|
| Blood |
275 |
| Dermatology |
108 |
| Endocrine |
358 |
| Oncology & Immunomodulators |
7,112 |
| Respiratory |
774 |
| Sensory Organs |
875 |
| Other Rx & OTC Pharma |
19 |
|
| EvaluatePharma® Coverage of Marketed and Pipeline Products |
|
|
|
|